<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alex Reyentovich, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Holger Thiele, MD, FESC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephan Windecker, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 15, 2020.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cardiogenic shock (CS) is a clinical condition of inadequate tissue (end-organ) perfusion due to cardiac dysfunction. The definition includes the following hemodynamic parameters: persistent hypotension (systolic blood pressure &lt;80 to 90 mmHg or mean arterial pressure 30 mmHg lower than baseline) with severe reduction in the cardiac index (&lt;1.8 L/min per m<sup>2</sup> without support or &lt;2 to 2.2 L/min per m<sup>2</sup> with support) and adequate or elevated filling pressures [<a href="#rid1">1</a>]. </p><p>The most common etiology of CS is an acute myocardial infarction (MI; usually ST-elevation MI [STEMI]) with left ventricular failure, but it can also be caused by mechanical complications such as acute mitral regurgitation or rupture of either the ventricular septal or free walls. However, any cause of acute severe left or right ventricular dysfunction may lead to CS.</p><p>The prognosis and therapy of CS complicating acute MI will be reviewed here. The pathophysiology, clinical manifestations, and diagnosis of this disorder are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/44.html" rel="external">"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction"</a>.)</p><p class="headingAnchor" id="H4131713329"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence of CS complicating acute MI has been falling since the mid-1970s. In a report from one United States metropolitan area, the incidence of CS was around 7 percent between 1975 and 1990 and has decreased to between 5.5 to 6.0 percent since then [<a href="#rid2">2</a>]. The decrease in the incidence of shock and the associated improvement in overall mortality in part reflect increased use of coronary reperfusion strategies for MI, including primary percutaneous coronary intervention and fibrinolytic therapy, which by restoring patency to the infarct-related artery, can limit infarct size, reduce the risk of shock, and improve survival [<a href="#rid3">3-6</a>]. </p><p class="headingAnchor" id="H3608981562"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>For patients determined to have cardiogenic shock (see <a class="local">'Introduction'</a> above), we take the following sequential steps in management:</p><p class="bulletIndent1"><span class="glyph">●</span>Ventilatory support is initiated in patients who meet criteria. (See <a class="local">'Ventilatory support'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemodynamic support is initiated, usually with inotropic agents or with <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> in patients who have marked hypotension (ie, systolic blood pressure &lt;80 mmHg). We do not routinely place an intraaortic balloon pump. Benefit may exist in patients with mechanical defects and selected other patients who are rapidly deteriorating. (See <a class="local">'Hemodynamic support'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We avoid beta blockers. We give <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> 325 mg but do not give an oral P2Y<sub>12 </sub>receptor blocker until after diagnostic coronary angiography. (See <a class="local">'Medical therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H3728388542"><span class="h1">VENTILATORY SUPPORT</span><span class="headingEndMark"> — </span>Ventilatory support may be required for several reasons in patients with CS (see  <a class="medical medical_review" href="/z/d/html/1640.html" rel="external">"Overview of initiating invasive mechanical ventilation in adults in the intensive care unit"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>To protect the airway and maintain oxygen supply in patients with a deterioration in consciousness or cardiac arrest.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To treat acute respiratory failure, most often due to cardiogenic pulmonary edema. (See  <a class="medical medical_review" href="/z/d/html/3454.html" rel="external">"Treatment of acute decompensated heart failure: General considerations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To raise the arterial pH in metabolic acidosis. (See  <a class="medical medical_review" href="/z/d/html/2294.html" rel="external">"Bicarbonate therapy in lactic acidosis"</a>.)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">HEMODYNAMIC SUPPORT</span><span class="headingEndMark"> — </span>Prompt management of hypotension and hypoperfusion is essential. Both pharmacologic and nonpharmacologic methods of circulatory support are rapidly employed to reverse hypotension, maintain vital organ perfusion, and maintain coronary perfusion pressure [<a href="#rid7">7-10</a>]. </p><p>Hemodynamic monitoring may be useful in patients with refractory shock despite revascularization. However, reperfusion therapy should not be delayed for insertion of a balloon-tipped pulmonary artery catheter. (See <a class="local">'Role of pulmonary artery catheter'</a> below.)</p><p class="headingAnchor" id="H4038438632"><span class="h2">Volume status</span><span class="headingEndMark"> — </span>Careful attention should be given to volume status, although it may be difficult to evaluate in CS patients [<a href="#rid11">11</a>]. Hypovolemia may be present, particularly in the setting of diuretic use or vomiting. An empiric intravenous volume challenge of 250 mL of isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> can be given prior to right heart catheterization in patients with suspected CS when there is no evidence of pulmonary congestion on physical examination or chest radiograph and the patient is not in respiratory distress [<a href="#rid12">12</a>]. Overly vigorous fluid challenges in patients with extensive left ventricular infarction, particularly older adults, will result in pulmonary edema and should be avoided. On the other hand, patients with volume overload and cardiogenic pulmonary edema without hypotension may require therapy with diuretics, <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, supplemental oxygen, and vasodilators. The management of this complication is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3454.html" rel="external">"Treatment of acute decompensated heart failure: General considerations"</a>.) </p><p>CS may be secondary to right ventricular shock due to a right ventricular MI. Volume repletion has a role in these patients that have low right-sided filling pressures with hypovolemia. However, excess fluid administration results in a shift of the interventricular septum into the left ventricle, with restriction to left ventricular filling in patients with severe right ventricular dysfunction. (See  <a class="medical medical_review" href="/z/d/html/75.html" rel="external">"Right ventricular myocardial infarction", section on 'Optimization of right ventricular preload'</a>.)</p><p class="headingAnchor" id="H1519501460"><span class="h2">Vasopressors and inotropes</span><span class="headingEndMark"> — </span>Based on the lower rate of arrhythmias and the trend toward lower mortality presented below, our experts suggest starting with <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a>. We attempt to minimize the number of agents and their dose. </p><p>In some patients, measurement of hemodynamic parameters such as cardiac output and arterial pressure (as well as the calculation of systemic vascular resistance) with an arterial line and a pulmonary artery catheter may guide the choice of vasopressors and inotropes. However, there is no evidence that titrating medications based on hemodynamics improves outcomes. (See  <a class="medical medical_review" href="/z/d/html/1593.html" rel="external">"Pulmonary artery catheterization: Indications, contraindications, and complications in adults", section on 'Severe cardiogenic shock'</a> and  <a class="medical medical_review" href="/z/d/html/1595.html" rel="external">"Pulmonary artery catheterization: Interpretation of hemodynamic values and waveforms in adults"</a>.)</p><p>Sympathomimetic inotropic and vasopressor agents  (<a class="graphic graphic_table graphicRef99963" href="/z/d/graphic/99963.html" rel="external">table 1</a>) are the mainstay of hemodynamic support [<a href="#rid12">12</a>]. However, there is very little evidence to guide the use of one drug over another or a particular combination of drugs:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">Norepinephrine</a> is a potent vasopressor with some positive inotropic properties that may be used for rapid initial circulatory support for CS. The minimum required dose should be used. (See  <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">"Use of vasopressors and inotropes", section on 'Norepinephrine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">Dopamine</a> is a vasopressor; its effect varies based upon the dose range administered. At low doses, it has primarily positive inotropic effects but at higher doses it stimulates alpha adrenergic receptors, resulting in vasoconstriction and increased systemic vascular resistance. This may produce an undesirable elevation in pulmonary capillary wedge pressure (PCWP). The minimum required dose should be used. (See  <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">"Use of vasopressors and inotropes", section on 'Dopamine'</a>.)</p><p></p><p>While <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> has historically been chosen before <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a>, some evidence suggests that outcomes may be better with norepinephrine as the initial agent. In a trial of 1679 patients with circulatory shock due to varying etiologies (eg, septic, hypovolemic, and CS) who were randomly assigned to initial therapy with either dopamine or norepinephrine, there was a trend toward a higher rate of death at 28 days with dopamine, and there were significantly more arrhythmias, predominantly atrial fibrillation. There was no difference in the treatment effect based on shock type, including in the subset of 280 patients with CS [<a href="#rid13">13</a>].</p><p>We generally begin therapy with a vasopressor (usually <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a>) in patients with severe hypotension (ie, systolic blood pressure &lt;80 mmHg). The administration of <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a>, an inotropic agent  (<a class="graphic graphic_table graphicRef99963" href="/z/d/graphic/99963.html" rel="external">table 1</a>), is limited to less sick patients with a low cardiac index, high PCWP, and borderline low blood pressure but without severe hypotension. Nonhypotensive patients in a low output state with high PCWP can also be treated with dobutamine plus a vasodilator (intravenous <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> or <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a>). This combination will further reduce both afterload and preload. (See  <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">"Use of vasopressors and inotropes", section on 'Dobutamine'</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Intraaortic balloon pump</span><span class="headingEndMark"> — </span>The available evidence does not support the routine use of an intraaortic balloon pump (IABP) in most patients with acute MI complicated by CS in whom primary percutaneous coronary intervention (PCI) is attempted or performed or in whom fibrinolytic therapy is administered. However, benefit may exist in patients with mechanical defects (such as mitral regurgitation or a ventricular septal defect) and selected other patients who are rapidly deteriorating. (See  <a class="medical medical_review" href="/z/d/html/1482.html" rel="external">"Intraaortic balloon pump counterpulsation"</a> and  <a class="medical medical_review" href="/z/d/html/63.html" rel="external">"Acute myocardial infarction: Mechanical complications", section on 'Rupture of the interventricular septum'</a> and  <a class="medical medical_review" href="/z/d/html/63.html" rel="external">"Acute myocardial infarction: Mechanical complications", section on 'Papillary muscle rupture'</a>.)</p><p>The best evidence against the routine use of IABP for patients with MI comes from the IABP-SHOCK II trial in which 600 patients with CS complicating acute MI (ST-elevation and non-ST elevation MI) were randomly assigned to the device or no device [<a href="#rid14">14</a>]. All patients were expected to undergo early revascularization (predominantly with PCI) and to receive best available medical care. At 30 days, there was no difference in the rate of all-cause mortality (39.7 versus 41.3 percent, respectively; relative risk 0.96, 95% CI 0.79-1.17). There were no significant differences in secondary end points such as length of stay in the intensive care unit, renal function, or the rates of major bleeding, peripheral ischemic complications, sepsis, or stroke. There was no difference in mortality at long-term follow-up of 12 months and 6.2 years (52 versus 51 and 66.3 versus 67.0 percent, respectively) [<a href="#rid15">15,16</a>]. A 2015 meta-analysis of seven studies (n = 790), including IABP-SHOCK, came to similar conclusions [<a href="#rid17">17</a>]. </p><p>One weakness of the study was crossover of patients in the control group to IABP for reasons other than the development of a mechanical complication (26 of 30 insertions were thought to be protocol violations). However, a per-protocol adjusted analysis that excluded patients who crossed over came to the same conclusions. It is possible that rapidly deteriorating patients may not have been enrolled and if enrolled, crossed over; the study cohort may represent those who stabilized on vasopressor/inotropic support. Thus, the trial results may not apply to severe shock with rapid deterioration. Further data and longer follow-up are needed to better understand subsets that may benefit from IABP.</p><p>Two earlier observational studies support the findings in IABP-SHOCK II [<a href="#rid18">18-20</a>]. </p><p>For those patients with CS undergoing PCI in whom an IABP is chosen, the optimal timing of placement is unknown, as the observational evidence is conflicting. In IABP-SHOCK II, there was no difference in outcomes between those who received an IABP before or after PCI. In a study of 48 patients with MI and CS, a significantly lower in-hospital mortality rate at 30 days (19 versus 69 percent) was found in those who received the IABP before as opposed to after PCI [<a href="#rid21">21</a>]. However, an earlier analysis from the SHOCK trial registry suggested that the mortality was similar whether IABP was placed before or after PCI [<a href="#rid22">22</a>].</p><p>For patients whose hemodynamic parameters and clinical status are rapidly deteriorating while on vasopressor and inotropic support after revascularization, and who are candidates for bridge to transplantation or durable ventricular assist device, IABP is not as effective for hemodynamic support as other temporary mechanical circulatory support devices.</p><p>The role of IABP in MI patients treated with fibrinolytic therapy who will be transferred for possible revascularization is not well established, as there is little evidence that can be used to guide the formation of recommendations. (See  <a class="medical medical_review" href="/z/d/html/91.html" rel="external">"Diagnosis and management of failed fibrinolysis or threatened reocclusion in acute ST-elevation myocardial infarction", section on 'Primary failure'</a>.)</p><p class="headingAnchor" id="H26"><span class="h2">Other mechanical devices</span><span class="headingEndMark"> — </span>Though outcome evidence is lacking, temporary mechanical circulatory support (MCS) devices are increasingly being used in patients with CS. The selection of devices is usually dependent on center-specific experience and whether the patient requires univentricular or biventricular support. (See  <a class="medical medical_review" href="/z/d/html/1492.html" rel="external">"Short-term mechanical circulatory assist devices", section on 'Non-IABP percutaneous circulatory devices'</a>.)</p><p>These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Left ventricular and biventricular assist devices. In the setting of CS, these surgically implanted devices are usually placed as a bridge to recovery in patients who had rapid reperfusion but with persistent hypoperfusion, or as a bridge to transplantation or a durable left ventricular assist device (LVAD) in eligible patients in whom ventricular function is not expected to recover.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Percutaneous left atrial-to-femoral arterial ventricular assist device. This device (TandemHeart) is placed via the femoral vein and across the interatrial septum to provide temporary circulatory support while performing high-risk PCI or awaiting ventricular recovery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Percutaneous cardiopulmonary bypass support with use of an extracorporeal membrane oxygenator (ECMO) may be utilized when oxygenation is severely impaired or when rapid/bedside biventricular support is necessary for urgent stabilization [<a href="#rid23">23,24</a>]. </p><p></p><p class="bulletIndent1">In critically ill patients with multi-organ failure secondary to CS, a strategy of using ECMO to stabilize the patient and allow organ function recovery, followed by a delayed coronary artery bypass graft surgery, could be considered. This strategy might be particularly useful in patients who present late (more than six hours after initiation of symptoms) and in patients with mechanical complications of MI [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">"Extracorporeal life support in adults in the intensive care unit: Overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Percutaneous transvalvular LVAD. This device (Impella 2.5 or Impella CP) is placed via the femoral artery, retrograde across the aortic valve into the left ventricle. It has a microaxial pump that decompresses the left ventricle and delivers a maximum flow of 2.5 to 4.0 L/min into the ascending aorta. In a multicenter observational registry of 120 patients with CS after acute MI who received the Impella 2.5 device following initial IABP support, 30-day mortality was 64.2 percent [<a href="#rid26">26</a>]. Without a comparison group, we do not know how this would compare with no device or with other devices. </p><p></p><p class="bulletIndent1">In a 2019 retrospective analysis, the use of Impella was not associated with lower 30-day mortality compared with matched patients from the IABP-SHOCK trial treated with an IABP or medical therapy [<a href="#rid27">27</a>]. In April 2016, the US Food and Drug Administration approved the Impella device for use in acute MI-related CS based on circulatory support effect, not based on improved clinical outcomes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Impella RP System (Abiomed, United States) is a right ventricular assist device that provides peripherally-placed circulatory support in patients with refractory right ventricular shock. The pump is inserted via the femoral vein, into the right atrium, and through to the pulmonary artery, and can provide flow of up to 5 L/min [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several small randomized trials have compared percutaneous temporary LVAD support with IABP support in patients with CS after an acute MI [<a href="#rid29">29-31</a>]. Two meta-analyses have evaluated mortality using data from these small trials:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a 2017 meta-analysis of 148 patients randomly assigned to either TandemHeart or Impella VAD or an IABP, there was no difference in 30-day mortality (risk ratio [RR] 1.01, 95% CI 0.70-1.44, p = 0.98) for percutaneous LVAD support compared with IABP control [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a second 2017 meta-analysis that evaluated 95 patients randomly assigned to Impella or IABP, there was no difference in mortality at either 30 days (RR 0.99, 95% CI 0.62-1.58) or at six months (RR 1.15, 95% CI 0.74-1.48) between the Impella and the IABP cohort [<a href="#rid33">33</a>].</p><p></p><p>MCS devices were used in 3.1 percent of the cases reported in the National Cardiovascular Data Registry. In these cases, MCS was initiated before revascularization 27.7 percent of the time, during the revascularization procedure 49.9 percent, and 22.4 percent post-procedure [<a href="#rid34">34</a>]. Appropriately powered randomized trials are needed to assess whether use of MCS improves clinical outcomes, and to define the optimal strategy for MCS use in CS. The utilization of these devices is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1492.html" rel="external">"Short-term mechanical circulatory assist devices"</a>.)</p><p class="headingAnchor" id="H2934001346"><span class="h2">Role of pulmonary artery catheter</span><span class="headingEndMark"> — </span>Pulmonary artery catheters may be used to guide management of patients with shock and support treatment decisions [<a href="#rid35">35</a>]. However, their use in CS patients, with or without mechanical circulatory support, has not been proven to save lives. The use of pulmonary artery catheters has not been systematically evaluated in randomized clinical trials. Experts have widely differing views on their utility. Pulmonary artery catheter use may assist in device selection and weaning of patients in CS managed with mechanical circulatory support devices [<a href="#rid36">36</a>]. </p><p class="headingAnchor" id="H256945979"><span class="h1">MEDICAL THERAPY</span><span class="headingEndMark"> — </span>For patients with CS associated with acute myocardial infarction (MI), we use the following approach to drug treatment:</p><p class="bulletIndent1"><span class="glyph">●</span>Beta blockers should be avoided despite the fact that in the broad population of patients with acute MI, beta blockers are given early. In patients with CS or "pre-shock," in which the cardiac output is diminished but hypotension has not yet developed, drugs that have negative inotropic activity will likely worsen the clinical situation. Often, tachycardia is a reflection of response to low stroke volume in order to maintain cardiac output. (See  <a class="medical medical_review" href="/z/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction"</a> and  <a class="medical medical_review" href="/z/d/html/68.html" rel="external">"Overview of the acute management of non-ST-elevation acute coronary syndromes", section on 'Initial medical therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with CS in whom revascularization is planned, we give <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> 325 mg. We do not give an oral P2Y<sub>12 </sub>receptor blocker until after diagnostic coronary angiography in the event that coronary artery bypass surgery needs to be performed. (See  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Summary and recommendations'</a> and  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy", section on 'Summary and recommendations'</a>.)</p><p></p><p class="headingAnchor" id="H28"><span class="h1">REPERFUSION/REVASCULARIZATION</span><span class="headingEndMark"> — </span>Early, successful revascularization improves outcomes compared with medical therapy. Some patients will require only percutaneous coronary intervention (PCI) of the infarct-related artery, others may require immediate coronary artery bypass surgery (CABG), and some may require both. This may involve emergent percutaneous recanalization of the infarct-related artery in the catheterization laboratory followed by emergent/urgent or staged revascularization with CABG.</p><p class="headingAnchor" id="H1138686271"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>Our recommendations for the use of reperfusion therapy in patients with MI complicated by CS are similar to those for most patients with MI and differ principally in the level of evidence. For many patients, we proceed with immediate PCI of culprit lesions rather than CABG due to the much shorter time needed to establish reperfusion. (See  <a class="medical medical_review" href="/z/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy", section on 'Fibrinolysis'</a>.)</p><p>Our approach to reperfusion is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Immediate CABG is the reperfusion treatment of choice for patients with associated mechanical complications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with ST-elevation MI (STEMI), revascularization with either PCI or CABG is preferred to fibrinolytic therapy if it can be performed in a timely manner (within 120 minutes from initial hospital presentation for PCI) [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy", section on 'Summary and recommendations'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For MI (either STEMI or non-ST-elevation MI [NSTEMI]) patients with one- or two-vessel coronary disease and technically suitable lesions, immediate PCI of the culprit vessel is preferred to CABG [<a href="#rid38">38</a>]. (See <a class="local">'Percutaneous coronary intervention'</a> below.)</p><p></p><p class="bulletIndent1">Immediate reperfusion with PCI is also preferred to CABG for amenable severe stenosis or total occlusion of the left main coronary artery, particularly if it is due to thrombotic occlusion. (See <a class="local">'Left main coronary artery disease'</a> below.)</p><p></p><p class="bulletIndent1">Patients with advanced three-vessel disease, with or without left main coronary artery disease, who have no identifiable single culprit lesion should be considered for immediate CABG if available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients admitted to hospitals without facilities for revascularization who do not have contraindications to invasive care should be immediately transferred to a tertiary care center with such facilities [<a href="#rid12">12</a>]. If there is an anticipated long delay in transport for cardiac catheterization <strong>and</strong> the risks of fibrinolysis are low <strong>and</strong> the duration of MI symptoms is less than three hours, we recommend rapid initiation of fibrinolytic therapy (&lt;30 minutes) prior to transfer. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who survive initial therapy that does not include emergency PCI or CABG should be referred for immediate coronary angiography and potential revascularization [<a href="#rid12">12</a>]. This recommendation is based upon the high prevalence of a low left ventricular ejection fraction and three-vessel or left main coronary artery disease [<a href="#rid39">39</a>], settings in which revascularization is associated with a long-term reduction in mortality.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with ongoing evidence of systemic hypoperfusion despite revascularization and inotropic therapy (refractory CS) who may be candidates for transplantation or durable left ventricular assist device therapy (LVAD), we typically employ initiation of temporary mechanical circulatory support. Device selection is driven by the degree of hypoperfusion and whether the patient has univentricular or biventricular involvement (see <a class="local">'Other mechanical devices'</a> above). Device choice and device optimization may be driven by data from continuous right heart catheterization monitoring in this cohort of patients. (See <a class="local">'Role of pulmonary artery catheter'</a> above.) </p><p></p><p class="headingAnchor" id="H29"><span class="h2">Fibrinolysis</span><span class="headingEndMark"> — </span>Although reperfusion can be established with fibrinolysis in patients with STEMI, we prefer direct revascularization with either PCI or CABG. Fibrinolysis is recommended if PCI is not possible or if it is significantly delayed [<a href="#rid40">40,41</a>]. (See  <a class="medical medical_review" href="/z/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"</a> and  <a class="medical medical_review" href="/z/d/html/55.html" rel="external">"Acute ST-elevation myocardial infarction: The use of fibrinolytic therapy"</a>.)</p><p>Based upon the apparent benefit in those who did not receive immediate revascularization and the absence of adverse effects in those who underwent invasive procedures, fibrinolytic therapy should be given to patients who present to a facility without primary PCI and who cannot be transferred for primary PCI capability in a timely manner, particularly those who present within three hours of symptoms. However, all patients should be transferred to a PCI-capable facility as soon as possible. </p><p class="headingAnchor" id="H32"><span class="h2">Percutaneous coronary intervention</span><span class="headingEndMark"> — </span>In appropriate patients, PCI is preferred to no reperfusion or to fibrinolysis for patients with CS complicating acute STEMI and NSTEMI [<a href="#rid42">42-47</a>] (see <a class="local">'Our approach'</a> above). Immediate PCI should be performed on the culprit lesion(s) of the infarct-related artery. For most patients with CS and acute MI, we do not perform nonculprit lesion PCI. (See  <a class="medical medical_review" href="/z/d/html/103273.html" rel="external">"Acute coronary syndromes: Approach to nonculprit lesions"</a>.)</p><p>Nonrandomized [<a href="#rid45">45</a>] and randomized trials [<a href="#rid46">46</a>] have shown mortality benefit to early revascularization with PCI. Patients with CS on admission have a higher in-hospital mortality than the majority of patients who develop shock after hospitalization [<a href="#rid48">48,49</a>]. However, in the SHOCK trial and registry, patients with shock on admission derived the same in-hospital mortality benefit from emergency revascularization (60 versus 82 percent) as those who developed shock later (46 versus 62 percent) [<a href="#rid48">48</a>]. </p><p>A 2017 meta-analysis of 10 cohort studies that included over 6000 patients with CS showed a higher mortality with multivessel PCI than with culprit-lesion-only PCI (37.5 versus 28.8 percent; p = 0.001) [<a href="#rid50">50</a>]. The CULPRIT-SHOCK trial, published after the meta-analysis, randomly assigned 706 patients with both STEMI and NSTEMI with CS to PCI of the culprit lesion only, with the option of stage revascularization of nonculprit lesions or immediate multivessel PCI [<a href="#rid51">51</a>]. Staged revascularization was performed in 17.7 percent of the culprit-lesion-only group. The following findings were noted: </p><p class="bulletIndent1"><span class="glyph">●</span>At 30 days, the primary end point (a composite of death or renal failure leading to renal-replacement therapy) occurred less often in the culprit-lesion-only group (45.9 versus 55.4 percent; relative risk [RR] 0.83, 95% CI 0.71-0.96). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At 30 days, the secondary end point (all-cause death) occurred less often in the culprit-lesion-only group (RR 0.84, 95% CI 0.72-0.98). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At one year, death occurred in 50.0 and 56.9 percent of the two groups, respectively (RR 0.88, 95% CI 0.76-1.01) [<a href="#rid52">52</a>]. </p><p></p><p class="bulletIndent1">The rate of a composite of death or recurrent infarction was 50.9 and 58.4 percent, respectively (RR 0.87, 95% CI 0.76-1.00). Repeat revascularization occurred more often with culprit-only PCI (32.3 versus 9.4 percent; RR 3.44, 95% CI 2.39-4.95) as did rehospitalization for heart failure (5.2 versus 1.2 percent; RR 4.46, 95% CI 1.53-13.04). </p><p></p><p class="headingAnchor" id="H4215440555"><span class="h3">Left main coronary artery disease</span><span class="headingEndMark"> — </span>Patients with CS who have an occluded or severely stenosed left main coronary artery present complex clinical challenges. (See  <a class="medical medical_review" href="/z/d/html/1555.html" rel="external">"Left main coronary artery disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Immediate CABG is the reperfusion treatment of choice if there are associated mechanical complications. (See  <a class="medical medical_review" href="/z/d/html/63.html" rel="external">"Acute myocardial infarction: Mechanical complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients without mechanical complications, and when the left main coronary artery is the culprit lesion on angiography (eg, thrombotic occlusion, high-grade lesion), we proceed with immediate PCI in a manner analogous to primary PCI in STEMI. The rationale is to provide reperfusion therapy as rapidly as possible. Registry data show that PCI of the left main coronary artery in shock is feasible, is used more often than CABG, and is performed much earlier. Although adjustment for covariates, including considering PCI and CABG as time-varying covariates, suggests better outcomes for CABG, the data are confounded by selection of lower-risk patients for CABG who on average survived for several days [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immediate CABG should be considered for patients with left main coronary artery stenosis associated with severe three-vessel disease, particularly if a high SYNTAX score is present. (See <a class="local">'Coronary artery bypass graft surgery'</a> below and  <a class="medical medical_review" href="/z/d/html/1579.html" rel="external">"Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention", section on 'Outcomes based on lesion severity'</a>.)</p><p></p><p class="headingAnchor" id="H34"><span class="h3">Determinants of outcomes</span><span class="headingEndMark"> — </span>The clinical response to primary PCI is highly variable. While some patients improve rapidly, others show no immediate hemodynamic improvement, and a few transiently deteriorate after reperfusion is established, particularly if there is late reperfusion. This is also true for late reperfusion with fibrinolysis. Data from the nonrandomized SHOCK trial registry suggest that the in-hospital mortality after PCI is related to the degree of reperfusion achieved in the infarct-related artery [<a href="#rid54">54</a>]. Among 276 patients undergoing PCI, the mortality for Thrombolysis in Myocardial Infarction (TIMI) grade 3 (normal), grade 2, or grade 0/1 flow was 33, 50, and 86 percent, respectively. A similar relationship to TIMI flow grade was noted in a report from the ALKK primary PCI registry in Germany (37, 66, and 78 percent in-hospital mortality, respectively) [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/z/d/html/91.html" rel="external">"Diagnosis and management of failed fibrinolysis or threatened reocclusion in acute ST-elevation myocardial infarction", section on 'Primary failure'</a>.)</p><p>The time from symptom onset to PCI may be another determinant of outcome. In the ALKK report, the in-hospital mortality was 44 percent in patients receiving primary and rescue PCI, as well as urgent CABG, within three hours from symptom onset; 45 percent from three to six hours; 54 percent from 6 to 12 hours; and 58 percent from 12 to 24 hours [<a href="#rid55">55</a>]. However, the benefits of primary PCI were seen in both early and late presenters in the SHOCK trial [<a href="#rid46">46</a>]. As a result, late presenters should not be denied emergency revascularization based upon timing alone. (See <a class="local">'Percutaneous coronary intervention'</a> above.)</p><p class="headingAnchor" id="H36"><span class="h2">Coronary artery bypass graft surgery</span><span class="headingEndMark"> — </span>The majority of patients with CS after MI have significant left main coronary artery or three-vessel disease (16 and 53 percent, respectively, in the SHOCK trial registry) [<a href="#rid39">39</a>]. In such patients, the ability to achieve complete revascularization makes CABG a potentially critical therapeutic strategy. A surgical approach also permits the correction of concomitant severe mitral regurgitation, which is often present. Pooled data on 370 patients in 22 studies revealed an in-hospital mortality rate of 36 percent when CABG was performed during the hospitalization for acute MI with CS [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/47.html" rel="external">"Coronary artery bypass graft surgery in patients with acute ST-elevation myocardial infarction", section on 'Cardiogenic shock'</a>.)</p><p>The relatively low mortality rate in these nonrandomized series may reflect a true benefit or selection bias in which patients at lowest risk are selected for CABG. However, similar findings (41 percent overall mortality) were noted in the patients who underwent emergency CABG in the SHOCK trial within six hours of randomization [<a href="#rid46">46</a>]. Despite this benefit, CABG is underutilized in the community setting. In a review from the National Registry of Myocardial Infarction of 25,311 patients with CS seen from 1995 to 2004 in the United States, the overall rate of immediate CABG was stable at about 3 percent [<a href="#rid56">56</a>].</p><p>The relative efficacy of PCI and CABG was evaluated in the 128 patients with predominant left ventricular failure who underwent emergency revascularization in the SHOCK trial [<a href="#rid57">57</a>]. Not surprisingly, the 47 patients (37 percent) who underwent CABG were significantly more likely to have diabetes and three-vessel or left main coronary artery disease; 85 percent of these patients received two or more grafts, and 52 percent received three or more grafts. Despite the more extensive disease in the CABG group, overall survival was similar to PCI at 30 days (57 versus 56 percent with PCI) and one year (47 versus 52 percent). The similar outcomes, despite the worse disease in patients undergoing CABG, may reflect in part the higher rate of complete revascularization (87 versus 23 percent with PCI).</p><p class="headingAnchor" id="H39"><span class="h2">Long-term outcome</span><span class="headingEndMark"> — </span>In addition to the short-term benefits, follow-up reports from the SHOCK trial demonstrated that the benefit of revascularization persists for many years. At one year, early revascularization was associated with a lower mortality rate (eg, 53 versus 66 percent) [<a href="#rid47">47</a>]. In addition, the patients who were assigned to emergency revascularization were significantly more likely to remain stable after discharge (71 versus 44 percent at one year) and less likely to worsen or die after 30 days (15 versus 34 percent) [<a href="#rid58">58</a>].</p><p>The mortality benefit persisted at six years (67 versus 80 percent with initial medical stabilization) [<a href="#rid59">59</a>]. The previously observed significant interaction between age and treatment effect was no longer evident on long-term follow-up.</p><p>Evidence of long-term benefit was also suggested in a subset analysis from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial of over 39,000 patients who were alive at 30 days after an acute MI, 1306 of whom had been in CS [<a href="#rid60">60</a>]. Revascularization within 30 days was performed in 44 percent of the patients with CS; the one-year mortality in these patients was significantly lower than those who were not revascularized (8 versus 15 percent, odds ratio 0.6 after adjusting for differences in baseline characteristics). Not surprisingly, the survivors of CS had higher one-year mortality than those without shock (12 versus 3 percent).</p><p class="headingAnchor" id="H1144770959"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The short-term prognosis of CS is directly related to the severity of the hemodynamic disorder. Patients most commonly succumb to multiorgan dysfunction due to ongoing organ hypoperfusion [<a href="#rid7">7</a>]. In-hospital mortality is over 50 percent [<a href="#rid61">61,62</a>]. In 2019, the Society for Cardiovascular Angiography and Intervention proposed a classification scheme for patients admitted to a cardiac intensive care unit with CS [<a href="#rid63">63</a>]. In a subsequent single-center study, patients were retrospectively categorized into one of five stages (of severity) of CS based on the presence or absence of hypotension/tachycardia, hypoperfusion, clinical deterioration, or refractory shock [<a href="#rid64">64</a>]. Each higher CS stage was significantly associated with increased hospital mortality. Although this classification system needs additional validation, it has the potential to predict the risk of short-term death.</p><p>Long-term survival in patients with myocardial infarction (MI) complicated by CS is improved with timely revascularization in the acute setting, and functional status and quality of life in most survivors are excellent [<a href="#rid58">58,59</a>]. However, in the Intraventricular Aortic Balloon Pump Cardiogenic Shock (IABP-SHOCK) trial (see <a class="local">'Intraaortic balloon pump'</a> above), mortality was approximately 67 percent at nearly six years [<a href="#rid16">16</a>].</p><p>The following have been identified as risk factors for short- and/or long-term mortality in CS:</p><p class="bulletIndent1"><span class="glyph">●</span>Increasing age; clinical signs of severe hypoperfusion such as oliguria, cold or clammy extremities, or biochemical evidence such as increasing lactate [<a href="#rid65">65,66</a>]; elevated creatinine; and neurological involvement such as history of stroke [<a href="#rid14">14,16,67</a>] and anoxic damage [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal hemodynamic parameters such as reduced mean arterial pressure (MAP) despite supportive therapies, reduced cardiac output (CO), cardiac index, and cardiac power index (MAP x CO/451 x body surface area in m<sup>2</sup>) [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possible non-ST-elevation MI as opposed to ST-elevation MI (STEMI) [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mortality varies significantly with the location of the culprit lesion and is higher in patients with a left main coronary artery or saphenous vein graft lesion than in those with circumflex, left anterior descending, or right coronary artery lesions (79 and 70 percent versus 37 to 42 percent). Right coronary culprit lesions were associated with the best prognosis [<a href="#rid70">70</a>]. Multivessel disease or prior coronary artery bypass graft surgery are also risk factors for mortality [<a href="#rid14">14,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Echocardiographic predictors of outcome are reduced left ventricular ejection fraction and worsening severity of mitral regurgitation [<a href="#rid70">70,71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The time from symptom onset to reperfusion is an important determinant of mortality in patients with STEMI who undergo primary percutaneous coronary intervention [<a href="#rid72">72,73</a>]. (See  <a class="medical medical_review" href="/z/d/html/72.html" rel="external">"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome"</a>.)</p><p></p><p class="headingAnchor" id="H2038313269"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114034.html" rel="external">"Society guideline links: Non-ST-elevation acute coronary syndromes (non-ST-elevation myocardial infarction)"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/113180.html" rel="external">"Society guideline links: ST-elevation myocardial infarction (STEMI)"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/119297.html" rel="external">"Society guideline links: Percutaneous coronary intervention"</a>.)</p><p class="headingAnchor" id="H42"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with cardiogenic shock (CS) and acute myocardial infarction (MI), we withhold beta blockers until hemodynamics have stabilized. If possible, we give <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> 325 mg but do not give a P2Y<sub>12</sub> receptor blocker. (See <a class="local">'Medical therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with CS and severe hypotension (systolic blood pressure &lt;80 mmHg), we recommend vasopressors for initial management (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Although there is no definitive evidence of the superiority of one vasopressor over another, we suggest beginning with <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> rather than <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Vasopressors and inotropes'</a> above.). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients in whom mechanical complications (eg, acute mitral regurgitation or rupture of the ventricular septum) are not present and for whom revascularization is planned, we recommend not routinely placing an intraaortic balloon pump (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Intraaortic balloon pump'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients with CS complicating MI should undergo an attempt at reperfusion. (See <a class="local">'Reperfusion/revascularization'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Our recommendations for the use of reperfusion therapy in patients with MI complicated by CS are similar to those for most patients with MI (see  <a class="medical medical_review" href="/z/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy", section on 'Summary and recommendations'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with ST-elevation myocardial infarction (MI), we recommend revascularization as opposed to fibrinolytic therapy (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). This recommendation requires that diagnostic coronary angiography be performed within 120 minutes of initial hospital presentation. </p><p></p><p class="bulletIndent2">For those patients who cannot undergo timely coronary angiography, we recommend fibrinolytic therapy rather than no immediate reperfusion (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with one- or two-vessel disease who do not have mechanical complications, we recommend percutaneous coronary intervention (PCI) of the infarct-related artery as opposed to coronary artery bypass graft surgery (CABG) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with three-vessel or left main coronary artery disease who do not have mechanical complications (eg, acute mitral regurgitation or rupture of either the ventricular septal or free walls), the decision to perform immediate PCI or emergency CABG, with or without PCI of the infarct-related artery, should be decided based on the availability of rapid CABG, and factors such as the likelihood of successful revascularization with PCI, the extent of disease, and the skill level/experience of the operators. Shock teams, which include interventional cardiologists and cardiac surgeons, should be involved in decision-making.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with mechanical complications should undergo immediate CABG and an attempt at repairing the mechanical defect.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with non-ST-elevation MI, we recommend that revascularization be performed as soon as possible as opposed to either fibrinolytic therapy or no reperfusion (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>).</p><p></p><p class="headingAnchor" id="H4489947"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Venu Menon, MD, Judith Hochman, MD, and Duane Pinto, MD, MPH, who contributed to previous versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation 2008; 117:686.</a></li><li><a class="nounderline abstract_t">Goldberg RJ, Spencer FA, Gore JM, et al. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 2009; 119:1211.</a></li><li><a class="nounderline abstract_t">Goldberg RJ, Gore JM, Thompson CA, Gurwitz JH. Recent magnitude of and temporal trends (1994-1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction: the second national registry of myocardial infarction. Am Heart J 2001; 141:65.</a></li><li><a class="nounderline abstract_t">Holmes DR Jr, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995; 26:668.</a></li><li><a class="nounderline abstract_t">Goldberg RJ, Samad NA, Yarzebski J, et al. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999; 340:1162.</a></li><li><a class="nounderline abstract_t">Meinertz T, Kasper W, Schumacher M, Just H. The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction. Am J Cardiol 1988; 62:347.</a></li><li><a class="nounderline abstract_t">Vallabhajosyula S, Dunlay SM, Prasad A, et al. Acute Noncardiac Organ Failure in Acute Myocardial Infarction With Cardiogenic Shock. J Am Coll Cardiol 2019; 73:1781.</a></li><li><a class="nounderline abstract_t">Vallabhajosyula S, Arora S, Lahewala S, et al. Temporary Mechanical Circulatory Support for Refractory Cardiogenic Shock Before Left Ventricular Assist Device Surgery. J Am Heart Assoc 2018; 7:e010193.</a></li><li><a class="nounderline abstract_t">Vallabhajosyula S, Arora S, Sakhuja A, et al. Trends, Predictors, and Outcomes of Temporary Mechanical Circulatory Support for Postcardiac Surgery Cardiogenic Shock. Am J Cardiol 2019; 123:489.</a></li><li><a class="nounderline abstract_t">Vallabhajosyula S, O'Horo JC, Antharam P, et al. Concomitant Intra-Aortic Balloon Pump Use in Cardiogenic Shock Requiring Veno-Arterial Extracorporeal Membrane Oxygenation. Circ Cardiovasc Interv 2018; 11:e006930.</a></li><li><a class="nounderline abstract_t">Menon V, White H, LeJemtel T, et al. The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol 2000; 36:1071.</a></li><li class="breakAll">Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).</li><li><a class="nounderline abstract_t">De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362:779.</a></li><li><a class="nounderline abstract_t">Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367:1287.</a></li><li><a class="nounderline abstract_t">Thiele H, Zeymer U, Neumann FJ, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 2013; 382:1638.</a></li><li><a class="nounderline abstract_t">Thiele H, Zeymer U, Thelemann N, et al. Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial. Circulation 2019; 139:395.</a></li><li><a class="nounderline abstract_t">Unverzagt S, Buerke M, de Waha A, et al. Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Database Syst Rev 2015; :CD007398.</a></li><li><a class="nounderline abstract_t">Barron HV, Every NR, Parsons LS, et al. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J 2001; 141:933.</a></li><li><a class="nounderline abstract_t">Chen EW, Canto JG, Parsons LS, et al. Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation 2003; 108:951.</a></li><li><a class="nounderline abstract_t">Sjauw KD, Engström AE, Vis MM, et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J 2009; 30:459.</a></li><li><a class="nounderline abstract_t">Abdel-Wahab M, Saad M, Kynast J, et al. Comparison of hospital mortality with intra-aortic balloon counterpulsation insertion before versus after primary percutaneous coronary intervention for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 2010; 105:967.</a></li><li><a class="nounderline abstract_t">Sanborn TA, Sleeper LA, Bates ER, et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36:1123.</a></li><li><a class="nounderline abstract_t">Russo JJ, Aleksova N, Pitcher I, et al. Left Ventricular Unloading During Extracorporeal Membrane Oxygenation in Patients With Cardiogenic Shock. J Am Coll Cardiol 2019; 73:654.</a></li><li><a class="nounderline abstract_t">Guglin M, Zucker MJ, Bazan VM, et al. Venoarterial ECMO for Adults: JACC Scientific Expert Panel. J Am Coll Cardiol 2019; 73:698.</a></li><li><a class="nounderline abstract_t">Bronshteyn I, Tran LK, Shahzad S. Extracorporeal membrane oxygenation (ECMO) as a bridge to surgical intervention in the critically ill patient. Am J Resp Crit Care Med 2017; 195:A5939.</a></li><li><a class="nounderline abstract_t">Lauten A, Engström AE, Jung C, et al. Percutaneous left-ventricular support with the Impella-2.5-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-registry. Circ Heart Fail 2013; 6:23.</a></li><li><a class="nounderline abstract_t">Schrage B, Ibrahim K, Loehn T, et al. Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock. Circulation 2019; 139:1249.</a></li><li><a class="nounderline abstract_t">Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37:267.</a></li><li><a class="nounderline abstract_t">Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005; 26:1276.</a></li><li><a class="nounderline abstract_t">Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 2008; 52:1584.</a></li><li><a class="nounderline abstract_t">Ouweneel DM, Eriksen E, Sjauw KD, et al. Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction. J Am Coll Cardiol 2017; 69:278.</a></li><li><a class="nounderline abstract_t">Thiele H, Jobs A, Ouweneel DM, et al. Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur Heart J 2017; 38:3523.</a></li><li><a class="nounderline abstract_t">Ouweneel DM, Eriksen E, Seyfarth M, Henriques JP. Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump for Treating Cardiogenic Shock: Meta-Analysis. J Am Coll Cardiol 2017; 69:358.</a></li><li><a class="nounderline abstract_t">Masoudi FA, Ponirakis A, de Lemos JA, et al. Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. J Am Coll Cardiol 2017; 69:1427.</a></li><li><a class="nounderline abstract_t">Vallabhajosyula S, Shankar A, Patlolla SH, et al. Pulmonary artery catheter use in acute myocardial infarction-cardiogenic shock. ESC Heart Fail 2020; 7:1234.</a></li><li><a class="nounderline abstract_t">Saxena A, Garan AR, Kapur NK, et al. Value of Hemodynamic Monitoring in Patients With Cardiogenic Shock Undergoing Mechanical Circulatory Support. Circulation 2020; 141:1184.</a></li><li><a class="nounderline abstract_t">Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39:119.</a></li><li><a class="nounderline abstract_t">Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003; 107:2998.</a></li><li><a class="nounderline abstract_t">Wong SC, Sanborn T, Sleeper LA, et al. Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36:1077.</a></li><li><a class="nounderline abstract_t">Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343:311.</a></li><li><a class="nounderline abstract_t">French JK, Feldman HA, Assmann SF, et al. Influence of thrombolytic therapy, with or without intra-aortic balloon counterpulsation, on 12-month survival in the SHOCK trial. Am Heart J 2003; 146:804.</a></li><li><a class="nounderline abstract_t">O'Neill WW. Angioplasty therapy of cardiogenic shock: are randomized trials necessary? J Am Coll Cardiol 1992; 19:915.</a></li><li><a class="nounderline abstract_t">Bates ER, Topol EJ. Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol 1991; 18:1077.</a></li><li><a class="nounderline abstract_t">Antoniucci D, Valenti R, Santoro GM, et al. Systematic direct angioplasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: in-hospital and long-term survival. J Am Coll Cardiol 1998; 31:294.</a></li><li><a class="nounderline abstract_t">Berger PB, Holmes DR Jr, Stebbins AL, et al. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. Circulation 1997; 96:122.</a></li><li><a class="nounderline abstract_t">Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341:625.</a></li><li><a class="nounderline abstract_t">Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001; 285:190.</a></li><li><a class="nounderline abstract_t">Jeger RV, Harkness SM, Ramanathan K, et al. Emergency revascularization in patients with cardiogenic shock on admission: a report from the SHOCK trial and registry. Eur Heart J 2006; 27:664.</a></li><li><a class="nounderline abstract_t">Webb JG, Sleeper LA, Buller CE, et al. Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36:1084.</a></li><li><a class="nounderline abstract_t">de Waha S, Jobs A, Eitel I, et al. Multivessel versus culprit lesion only percutaneous coronary intervention in cardiogenic shock complicating acute myocardial infarction: A systematic review and meta-analysis. Eur Heart J Acute Cardiovasc Care 2018; 7:28.</a></li><li><a class="nounderline abstract_t">Thiele H, Akin I, Sandri M, et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med 2017; 377:2419.</a></li><li><a class="nounderline abstract_t">Thiele H, Akin I, Sandri M, et al. One-Year Outcomes after PCI Strategies in Cardiogenic Shock. N Engl J Med 2018; 379:1699.</a></li><li><a class="nounderline abstract_t">Montalescot G, Brieger D, Eagle KA, et al. Unprotected left main revascularization in patients with acute coronary syndromes. Eur Heart J 2009; 30:2308.</a></li><li><a class="nounderline abstract_t">Webb JG, Sanborn TA, Sleeper LA, et al. Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry. Am Heart J 2001; 141:964.</a></li><li><a class="nounderline abstract_t">Zeymer U, Vogt A, Zahn R, et al. Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK). Eur Heart J 2004; 25:322.</a></li><li><a class="nounderline abstract_t">Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005; 294:448.</a></li><li><a class="nounderline abstract_t">White HD, Assmann SF, Sanborn TA, et al. Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial. Circulation 2005; 112:1992.</a></li><li><a class="nounderline abstract_t">Sleeper LA, Ramanathan K, Picard MH, et al. Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 2005; 46:266.</a></li><li><a class="nounderline abstract_t">Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006; 295:2511.</a></li><li><a class="nounderline abstract_t">Berger PB, Tuttle RH, Holmes DR Jr, et al. One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial. Circulation 1999; 99:873.</a></li><li><a class="nounderline abstract_t">Wayangankar SA, Bangalore S, McCoy LA, et al. Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction: A Report From the CathPCI Registry. JACC Cardiovasc Interv 2016; 9:341.</a></li><li><a class="nounderline abstract_t">Shah M, Patnaik S, Patel B, et al. Trends in mechanical circulatory support use and hospital mortality among patients with acute myocardial infarction and non-infarction related cardiogenic shock in the United States. Clin Res Cardiol 2018; 107:287.</a></li><li><a class="nounderline abstract_t">Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv 2019; 94:29.</a></li><li><a class="nounderline abstract_t">Jentzer JC, van Diepen S, Barsness GW, et al. Cardiogenic Shock Classification to Predict Mortality in the Cardiac Intensive Care Unit. J Am Coll Cardiol 2019; 74:2117.</a></li><li><a class="nounderline abstract_t">Harjola VP, Lassus J, Sionis A, et al. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail 2015; 17:501.</a></li><li><a class="nounderline abstract_t">Hasdai D, Holmes DR Jr, Califf RM, et al. Cardiogenic shock complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. Am Heart J 1999; 138:21.</a></li><li><a class="nounderline abstract_t">Sleeper LA, Reynolds HR, White HD, et al. A severity scoring system for risk assessment of patients with cardiogenic shock: a report from the SHOCK Trial and Registry. Am Heart J 2010; 160:443.</a></li><li><a class="nounderline abstract_t">Fincke R, Hochman JS, Lowe AM, et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol 2004; 44:340.</a></li><li><a class="nounderline abstract_t">Anderson ML, Peterson ED, Peng SA, et al. Differences in the profile, treatment, and prognosis of patients with cardiogenic shock by myocardial infarction classification: A report from NCDR. Circ Cardiovasc Qual Outcomes 2013; 6:708.</a></li><li><a class="nounderline abstract_t">Sanborn TA, Sleeper LA, Webb JG, et al. Correlates of one-year survival inpatients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial. J Am Coll Cardiol 2003; 42:1373.</a></li><li><a class="nounderline abstract_t">Picard MH, Davidoff R, Sleeper LA, et al. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation 2003; 107:279.</a></li><li><a class="nounderline abstract_t">Ortolani P, Marzocchi A, Marrozzini C, et al. Clinical impact of direct referral to primary percutaneous coronary intervention following pre-hospital diagnosis of ST-elevation myocardial infarction. Eur Heart J 2006; 27:1550.</a></li><li><a class="nounderline abstract_t">Scholz KH, Maier SKG, Maier LS, et al. Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial. Eur Heart J 2018; 39:1065.</a></li></ol></div><div id="topicVersionRevision">Topic 83 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18250279" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cardiogenic shock: current concepts and improving outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19237658" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136488" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Recent magnitude of and temporal trends (1994-1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction: the second national registry of myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7642857" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10202167" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Temporal trends in cardiogenic shock complicating acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3046283" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30975295" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acute Noncardiac Organ Failure in Acute Myocardial Infarction With Cardiogenic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30571481" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Temporary Mechanical Circulatory Support for Refractory Cardiogenic Shock Before Left Ventricular Assist Device Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30473325" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Trends, Predictors, and Outcomes of Temporary Mechanical Circulatory Support for Postcardiac Surgery Cardiogenic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30354593" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Concomitant Intra-Aortic Balloon Pump Use in Cardiogenic Shock Requiring Veno-Arterial Extracorporeal Membrane Oxygenation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10985707" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10985707" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20200382" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparison of dopamine and norepinephrine in the treatment of shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22920912" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Intraaortic balloon support for myocardial infarction with cardiogenic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24011548" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30586721" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25812932" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11376306" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12912817" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19168529" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20346314" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Comparison of hospital mortality with intra-aortic balloon counterpulsation insertion before versus after primary percutaneous coronary intervention for cardiogenic shock complicating acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10985715" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30765031" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Left Ventricular Unloading During Extracorporeal Membrane Oxygenation in Patients With Cardiogenic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30765037" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Venoarterial ECMO for Adults: JACC Scientific Expert Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Extracorporeal membrane oxygenation (ECMO) as a bridge to surgical intervention in the critically ill patient</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23212552" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Percutaneous left-ventricular support with the Impella-2.5-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30586755" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320110" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15734771" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19007597" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27810347" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020341" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27810348" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump for Treating Cardiogenic Shock: Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28025065" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32239806" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pulmonary artery catheter use in acute myocardial infarction-cardiogenic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32250695" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Value of Hemodynamic Monitoring in Patients With Cardiogenic Shock Undergoing Mechanical Circulatory Support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28886621" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12821585" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10985708" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7905143" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14597928" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Influence of thrombolytic therapy, with or without intra-aortic balloon counterpulsation, on 12-month survival in the SHOCK trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1552111" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Angioplasty therapy of cardiogenic shock: are randomized trials necessary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1894853" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9462570" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Systematic direct angioplasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: in-hospital and long-term survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9236426" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10460813" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11176812" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : One-year survival following early revascularization for cardiogenic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16423873" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Emergency revascularization in patients with cardiogenic shock on admission: a report from the SHOCK trial and registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10985709" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28703046" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Multivessel versus culprit lesion only percutaneous coronary intervention in cardiogenic shock complicating acute myocardial infarction: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29083953" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30145971" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : One-Year Outcomes after PCI Strategies in Cardiogenic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19720640" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Unprotected left main revascularization in patients with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11376311" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14984921" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16046651" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16186436" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16022953" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16757723" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10027808" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26803418" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction: A Report From the CathPCI Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29134345" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Trends in mechanical circulatory support use and hospital mortality among patients with acute myocardial infarction and non-infarction related cardiogenic shock in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31104355" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31548097" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cardiogenic Shock Classification to Predict Mortality in the Cardiac Intensive Care Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25820680" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical picture and risk prediction of short-term mortality in cardiogenic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10385759" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cardiogenic shock complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20826251" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A severity scoring system for risk assessment of patients with cardiogenic shock: a report from the SHOCK Trial and Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15261929" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24221834" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Differences in the profile, treatment, and prognosis of patients with cardiogenic shock by myocardial infarction classification: A report from NCDR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14563577" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Correlates of one-year survival inpatients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12538428" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16707549" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Clinical impact of direct referral to primary percutaneous coronary intervention following pre-hospital diagnosis of ST-elevation myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29452351" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
